Biobank for skin cancer collecting blood, tissue, and clinical data
Prospective Collection of Clinical Data and Human Body Material (HBM): Blood (Serum, Plasma, DNA) and Tissue of Cutaneous Melanoma and Non Melanoma Patients. Biobank Huidkanker
This project will collect blood, tissue, and clinical information from adults with melanoma or non‑melanoma skin cancer to build a biobank for future research.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 7500 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Universitaire Ziekenhuizen KU Leuven Academic / other |
| Locations | 1 site (Leuven, Vlaams-Brabant) |
| Trial ID | NCT07266142 on ClinicalTrials.gov |
What this trial studies
This is a prospective collection that gathers standardized clinical data, questionnaire responses, and human body material (blood: serum, plasma, DNA; and tissue) from adults diagnosed with cutaneous melanoma or non‑melanoma skin cancer. Participants provide informed consent, share medical and surgical history and risk factors, complete the Cancer Worry Scale, and give blood and residual or additional tissue samples when consented. Samples and linked clinical data are stored in a biobank under an umbrella protocol and may be used for future approved research via satellite protocols. The protocol does not assign treatments and is designed to support downstream biomarker and translational studies.
Who should consider this trial
Good fit: Adults (age ≥18) diagnosed with cutaneous melanoma or non‑melanoma skin cancer who can provide written informed consent and are willing to provide biological samples and clinical information.
Not a fit: Patients should not expect direct therapeutic benefit or immediate changes to their treatment from participation, since this protocol is for sample and data collection only.
Why it matters
Potential benefit: If successful, the biobank could accelerate research that leads to better diagnostics, biomarkers, and eventual improvements in personalized care for skin cancer patients.
How similar studies have performed: Cancer biobanks are an established approach and have previously enabled biomarker discoveries and translational research, so this protocol follows a well‑validated model.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures * Adult subjects (\>18 years of age) at time of enrolment. * Subjects diagnosed with cutaneous melanoma or Non-melanoma skin cancer. * Adult subjects able and willing to provide informed consent. Exclusion Criteria: * Subjects unable or not willing to provide informed consent. * Pregnancy (or willing to become pregnant) is NOT an exclusion criteria (unless specified in the respective satellite protocols.
Where this trial is running
Leuven, Vlaams-Brabant
- UZLeuven, Department of Dermatology — Leuven, Vlaams-Brabant, Belgium (Recruiting)
Study contacts
- Study coordinator: Annemiek Leeman, Prof. Dr.
- Email: annemiek.leeman@uzleuven.be
- Phone: 0032 016337950
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.